Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam 75 mg Powder and Diluent for Nebuliser Solution Versus Tobramycin Nebuliser Solution in an Intermittent Aerosolized Antibiotic Regimen, in Subjects With Cystic Fibrosis Followed by an Open-Label, Single Arm Extension

Next Previous
Trial Profile

An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam 75 mg Powder and Diluent for Nebuliser Solution Versus Tobramycin Nebuliser Solution in an Intermittent Aerosolized Antibiotic Regimen, in Subjects With Cystic Fibrosis Followed by an Open-Label, Single Arm Extension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aztreonam (Primary) ; Tobramycin
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 21 Apr 2012 Planned number of patients changed from 200 to 273 as reported by European Clinical Trials Database.
    • 22 Oct 2010 Gilead submitted data from this trial to the FDA in the third quarter of 2010 and plans to begin submitting data to international regulatory agencies by the end of 2010, according to a media release.
    • 21 Oct 2010 The second co-primary endpoint has been met and so aztreonam has now met the statistical definition of superiority, according to a Gilead Sciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top